5:15 - 6:00: Register
6:00: Registration closes
5:30 - 6:15: Food, networking, What's your [x]?
6:20 - 6:40: Welcome / Opening Remarks
6:40+: Moonshot pioneer pitches along with feedback from an esteemed panel. The core team is very excited about the talent that has been building for this event.
8:30: Closing remarks
"After the party, there's the after party."
Leonard Flom (Ophthalmology professor at NYU School of Medicine): He may have an ultraviolet photon-based cure for Ebola and HIV.
Norberto Guzman (AffinityCE): Immunoaffinity capillary electrophoresis (IACE) refers to a modular, portable, multi-dimensional point-of-care instrument that combines the technologies of immunoassay and analytical separation. This device can reduce the cost worldwide for access to expensive medical tests and treatments, and help practitioners obtain rapid and accurate diagnosis and prognosis of diseases.
John Kulp (bioleap): "The Arms Race between Nature’s evolution toolbox and our ability to develop therapies to attack mutating microbes, is not being won. To rapidly produce such therapies, we propose to employ the unprecedented capacity of cloud computing resources to assemble new drugs by linking chemical fragments that are found to bind to critical proteins in ways that avoid mutations. A public repository of chemical fragment maps for 1,000’s of proteins and 100’s of structural variations of such proteins would be made available on the Internet to the broad community of life sciences researchers. Web-based tools would enable them to construct and quantum mechanically evaluate candidate therapies in a highly automated fashion. This capability would vastly accelerate mankind’s ability to respond to the threats of pandemics from drug-resistant 'superbugs'."
Bodo Hoenen (Dev4x): "650 million children will only ever go to the most inadequate of schools, over 50 million will never go to school. We are building an autonomous self-schooling platform that runs on low cost phones and tablets that these children can use to teach themselves anything they need to reach for their dreams."
Rik Riman (Rutgers): His team is working on a reformulated process for concrete.
Wenting Zhang (Stevens Institute of Technology): “We have developed a new platform for reconstructing patient- specific cancer models (using multiply myeloma as an example) by using microfluidic devices. This new approach allows us to culture hard - to -preserve primary human tumor cells in vitro for personalized drug screening.”
Vincent Ogutu (Rutgers): “I would like to simulate teleportation by enabling people to project 3D holograms of their full body at their intended destination. Their hologram will interact with people at the destination and have the ability to move from one person to another as though they were actually moving in the room.”
What is Solve for X?
This is the 2nd qualifying event of GDG North Jersey's Solve for X (http://solveforx.gdgnorthjersey.com/) (SFX) campaign. What is Solve for X you may ask? SFX is a global initiative from Google [x] (http://en.wikipedia.org/wiki/Google_X) which aims to find pioneers in science and technology who are working on huge game changing “moonshots” and accelerating their progress to impact the world in positive ways.
How are we involved?
GDG North Jersey was selected as 1 of 12 sites in the world and 1 of only 2 in the USA to host an SFX as part of Google's first ever series of partner led events. At this event we will hear from some of the brightest minds in the region as they present their breakthrough solutions to huge problems in the world.
This event is open to anyone who would like to attend. Applications to present a moonshot at this event are open until Dec 28th. Follow the link below and click on "Submit Your Moonshot" to submit your concept and be considered for inclusion in the lineup.
* Note that we are also accepting submissions for our event at The Grommet (Boston vicinity) until Jan 5th and Stevens Institute (Hoboken, NJ) until Jan 7th. The Stevens event is also listed on our Meetup site.
Media coverage of the campaign has been picking up with a couple of mentions: